Manipulation of the Endocannabinoid System and its effects on ADHD-related behaviors and Dopaminergic and Norepinephrinergic Neurotransmission in an animal model
ADHD, Dopamine, Norepinephrine, Endocannabinoid System.
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by cognitive and behavioral dysfunctions, such as attention deficit, impulsivity, and hyperactivity. The neurobiological underpinnings involved in ADHD are not yet fully elucidated. Dopamine, which controls many vital physiological functions and complex behaviors, and norepinephrine, which is involved in attention processes, are neurotransmitters that appear to play an important role in several neuropsychiatric disorders, such as schizophrenia and ADHD. Evidence indicates that alterations in the dopaminergic and norepinephrinergic systems in the prefrontal cortex contribute significantly to its pathophysiology. Dopamine and norepinephrine transporters play central roles in the homeostasis of these neurotransmitters and in the modulation of executive functions. The endocannabinoid system (ECS), through the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG), CB1 and CB2 receptors, and enzymes involved in their synthesis and degradation, regulates neurobiological processes such as cognition, emotion, and memory. Studies indicate that the ECS functionally interacts with the dopaminergic and norepinephrinergic systems, suggesting a relevant modulatory role in the neurobiology of ADHD. Animal models such as DAT-KO mice, which have a deletion of the DAT gene, have been widely used to investigate the consequences of dopaminergic hyperfunction, demonstrating phenotypes compatible with ADHD symptoms. Thus, the analysis of the interaction between the ECS and the dopaminergic and norepinephrinergic systems may contribute to the advancement of the pathophysiological understanding of ADHD and open new therapeutic possibilities.